Drug News

Positive Outlook: AstraZeneca CEO Praises Interim Data from Lung Cancer Drug Trial

AstraZeneca’s Chief Executive, Pascal Soriot, expressed optimism about the interim data from a crucial lung cancer drug trial. The trial tested an experimental precision drug called datopotamab deruxtecan. While the results were released earlier, the company did not label them as “clinically meaningful,” which led to an 8% drop in the company’s shares.

Soriot addressed the issue during a media briefing after the release of better-than-expected quarterly results. He stated that the decision not to use the “clinically meaningful” description would become clear when the full results are disclosed, but he did not provide further details.

He emphasized that the overall data was very encouraging and described it as “statistically positive.” The company reaffirmed its commitment to proceed with filing the trial data with the U.S. Food and Drug Administration (FDA), which helped alleviate some investor concerns.

Susan Galbraith, the executive vice president of oncology R&D, reported that the FDA’s response to the data so far had been encouraging.

However, specific details about the timing of the final data release, the medical conference where it will be presented, or the timeline for seeking drug approval from the U.S. drug regulator were not disclosed by the executives during the briefing.


Dr. Oche Otorkpa PG Cert, MPH, PhD

Dr. Oche is a seasoned Public Health specialist who holds a post graduate certificate in Pharmacology and Therapeutics, an MPH, and a PhD both from Texila American University. He is a member of the International Society of Substance Use Professionals and a Fellow of the Royal Society for Public Health in the UK. He authored two books: "The Unseen Terrorist," published by AuthorHouse UK, and "The Night Before I Killed Addiction."
Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker